Stock & Company Details
Regeneron Pharmaceuticals, Inc. $REGN
Price:
N/A
N/A
101M
$84B
52 Week High:
N/A
10 Day Average Volume:
N/A
20.24
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
REGN technical indicators
Latest Regeneron Pharmaceuticals, Inc. (REGN) indicator readings as of 2026-10-29.
REGN's 14-day RSI is 61.4, in neutral territory. At $818.77 it is trading 11.1% above its 200-day moving average of $736.67, and above its 50-day average of $791.28. Price sits near the upper Bollinger Band ($715.37 to $843.14). ADX reads 23.7, sitting between trending and range-bound.
REGN backtested strategy results
How 4 rule-based strategies performed on Regeneron Pharmaceuticals, Inc. (REGN) over recent history, last backtested 2026-10-16. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +41.2% | 53% | 15 | -33.6% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -18.7% | 36% | 25 | -43.7% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -9.6% | 40% | 30 | -24.6% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -3.7% | 67% | 24 | -38.7% |
Overview
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Finance Bot
Ask your questions
Start by typing a question below.
